GlassScriptPhysician profile
Gene Sweetnam
NPI 1972560241
$12,929.04
in general payments reported to CMS, 2019-2025
27 companies · $2,933 in 2025
The $2,933 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $289 · 2021: $2,326 · 2022: $1,593 · 2023: $1,565 · 2024: $2,544 · 2025: $2,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,708 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Entertainment: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Entertainment | $133.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,174.32 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Eyevance Pharmaceuticals LLC | $1,598.21 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,505.87 | 2019-2021 | |
| Alcon Vision LLC | $1,244.35 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $977.98 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $766.97 | 2019-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $766.68 | 2019-2024 | Cequa |
| Biotissue Holdings INC. | $701.37 | 2023-2025 | |
| Lumenis Be INC | $550.31 | 2024 | Optilight |
| Abbvie INC. | $305.74 | 2023-2024 | Lumigan, Vuity |
| Sight Sciences, INC. | $261.61 | 2024-2025 | Tearcare System, Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $237.98 | 2023 | Syfovre |
| Maculogix, INC. | $178.79 | 2019-2021 | |
| Optos, INC. | $176.44 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $166.56 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $165.22 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $164.96 | 2023-2024 | Clarus, Cirrus Hd-Oct |
| Rxsight INC | $145.30 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $142.33 | 2021 | |
| Harrow Eye, LLC | $141.92 | 2025 | Vevye |
| Lkc Technologies, INC. | $133.43 | 2024 | |
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Shire North American Group INC | $121.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.59 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $61.57 | 2019 | |
| Horizon Therapeutics Plc | $22.95 | 2023 | Tepezza |
| Topcon Healthcare, INC. | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Sweetnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.